<?xml version='1.0' encoding='utf-8'?>
<document id="31999314"><sentence text="Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial."><entity charOffset="20-30" id="DDI-PubMed.31999314.s1.e0" text="rifampicin" /><entity charOffset="34-43" id="DDI-PubMed.31999314.s1.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.31999314.s1.e0" e2="DDI-PubMed.31999314.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31999314.s1.e0" e2="DDI-PubMed.31999314.s1.e1" /></sentence><sentence text="High-dose rifampicin is considered to shorten anti-TB treatment duration but its effect on antiretroviral metabolism is unknown"><entity charOffset="10-20" id="DDI-PubMed.31999314.s2.e0" text="rifampicin" /></sentence><sentence text="" /><sentence text="To assess the effect of doubling the rifampicin dose (to 20 mg/kg/day, R20) on efavirenz pharmacokinetics (PK) in HIV/TB coinfected patients"><entity charOffset="37-47" id="DDI-PubMed.31999314.s4.e0" text="rifampicin" /><entity charOffset="79-88" id="DDI-PubMed.31999314.s4.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.31999314.s4.e0" e2="DDI-PubMed.31999314.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31999314.s4.e0" e2="DDI-PubMed.31999314.s4.e1" /></sentence><sentence text="" /><sentence text="Open-label Phase 2 drug-drug interaction randomized trial" /><sentence text=" Pulmonary TB, ART-naive adults were randomized to R20 and either efavirenz 600 mg (EFV600) or 800 mg (EFV800), or rifampicin 10 mg/kg/day (R10) and EFV600 with a 1:1:1 ratio"><entity charOffset="66-75" id="DDI-PubMed.31999314.s7.e0" text="efavirenz" /><entity charOffset="84-90" id="DDI-PubMed.31999314.s7.e1" text="EFV600" /><entity charOffset="103-109" id="DDI-PubMed.31999314.s7.e2" text="EFV800" /><entity charOffset="115-125" id="DDI-PubMed.31999314.s7.e3" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e0" e2="DDI-PubMed.31999314.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e0" e2="DDI-PubMed.31999314.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e0" e2="DDI-PubMed.31999314.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e0" e2="DDI-PubMed.31999314.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e1" e2="DDI-PubMed.31999314.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e1" e2="DDI-PubMed.31999314.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e1" e2="DDI-PubMed.31999314.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e2" e2="DDI-PubMed.31999314.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31999314.s7.e2" e2="DDI-PubMed.31999314.s7.e3" /></sentence><sentence text=" Patients were first started on TB treatment and 2-4 weeks later started on ART" /><sentence text=" They were switched to R10 and EFV600 after 8 weeks" /><sentence text=" Full PK sampling was done 4 weeks (on rifampicin) and 24 weeks (off rifampicin) after ART initiation"><entity charOffset="39-49" id="DDI-PubMed.31999314.s10.e0" text="rifampicin" /><entity charOffset="69-79" id="DDI-PubMed.31999314.s10.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.31999314.s10.e0" e2="DDI-PubMed.31999314.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31999314.s10.e0" e2="DDI-PubMed.31999314.s10.e1" /></sentence><sentence text=" Transaminases, plasma HIV-1 RNA and sputum cultures were monitored" /><sentence text=" The efavirenz geometric mean ratio (GMR) of AUC at 4 and 24 weeks after ART initiation within the same patient was calculated in each arm and its 90% CI was compared with a preset range (0"><entity charOffset="5-14" id="DDI-PubMed.31999314.s12.e0" text="efavirenz" /></sentence><sentence text="70-1" /><sentence text="43)" /><sentence text="" /><sentence text="Of 98 enrolled patients (32 in the R20EFV600 arm, 33 in the R20EFV800 arm and 33 in the R10EFV600 arm), 87 had full PK sampling" /><sentence text=" For the R20EFV600, R20EFV800 and R10EFV600 arms, GMRs of efavirenz AUC were 0"><entity charOffset="58-67" id="DDI-PubMed.31999314.s17.e0" text="efavirenz" /></sentence><sentence text="87 (90% CI: 0" /><sentence text="75-1" /><sentence text="00), 1" /><sentence text="12 (90% CI: 0" /><sentence text="96-1" /><sentence text="30) and 0" /><sentence text="96 (90% CI: 0" /><sentence text="84-1" /><sentence text="10)" /><sentence text=" Twelve weeks after ART initiation, 78" /><sentence text="6%, 77" /><sentence text="4% and 72" /><sentence text="4% of patients had HIV-1 RNA below 100 copies/mL and 85" /><sentence text="7%, 86" /><sentence text="7% and 80" /><sentence text="0% had Week 8 culture conversion, respectively" /><sentence text=" Two patients per arm experienced a severe increase in transaminases" /><sentence text="" /><sentence text="Doubling the rifampicin dose had a small effect on efavirenz concentrations and was well tolerated"><entity charOffset="13-23" id="DDI-PubMed.31999314.s36.e0" text="rifampicin" /><entity charOffset="51-60" id="DDI-PubMed.31999314.s36.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.31999314.s36.e0" e2="DDI-PubMed.31999314.s36.e0" /><pair ddi="false" e1="DDI-PubMed.31999314.s36.e0" e2="DDI-PubMed.31999314.s36.e1" /></sentence><sentence text="" /></document>